Medical experts at Cleveland Clinic are highlighting new FDA-approved treatments and the critical importance of early detection for patients with cardiac amyloidosis.

These advancements matter because cardiac amyloidosis is a rare and systemic condition that historically carried a poor prognosis. The introduction of new drugs and combination therapies is now extending patient survival and improving the management of the disease.

Cardiac amyloidosis occurs when abnormal proteins build up in the heart muscle, causing it to become stiff and fail. According to a KPLC TV report, "Cardiac amyloidosis is a systemic disorder that affects the heart and can also affect other organs such as the kidneys and nervous system" [2].

The prevalence of systemic amyloidosis, which includes those with cardiac involvement, is estimated to affect between 50,000 and 150,000 people in the U.S. [2]. Because the symptoms often mimic other common heart conditions, clinicians said that early identification is the most effective way to improve patient outcomes.

Cardiologists at the Cleveland Clinic discussed these developments during a segment hosted by former health reporter Diana González [1]. They said that recent pharmaceutical approvals allow for more aggressive and targeted treatment plans, reducing the progression of protein deposits in the heart.

While the disease remains rare, the shift toward combination therapies marks a significant change in how the medical community approaches the disorder. Experts said that the goal is to stabilize organ function and prevent the systemic failure that often occurs when the kidneys, or nervous system, are simultaneously affected [1], [2].

“Cardiac amyloidosis is a systemic disorder that affects the heart and can also affect other organs.”

The transition from palliative care to active pharmaceutical intervention for cardiac amyloidosis reflects a broader trend in precision medicine. By targeting the specific protein misfolding responsible for the disease, these treatments shift the clinical focus from managing end-stage heart failure to slowing the disease's progression, potentially transforming a once-fatal diagnosis into a manageable chronic condition.